1
rich
Libsyn
https://www.libsyn.com
90
600
Reimagining Gene and Cell Therapy: Helen Sabzevari on Precigen’s Breakthroughs in Precision Medicine
In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company’s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen’s unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen’s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland’s BioHealth Capital Region has supported the company’s innovation and growth.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Dr. Helen Sabzevari is the President and CEO of Precigen, Inc., and a leading expert in immunotherapy-based therapeutics. She previously served in executive roles at Compass Therapeutics and Merck KGaA/EMD Serono, where she advanced numerous immuno-oncology programs. Dr. Sabzevari began her career at the National Cancer Institute and has been widely recognized for her leadership and scientific contributions, including honors from NIH, SITC, and Forbes.
BioTalk with Rich Bendis
http://www.biohealthinnovation.org/
<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/37257755/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/000000/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>
https://assets.libsyn.com/secure/content/190324940